Standard BioTools提交与Treeline合并相关S-4注册声明并披露早期TLN-121数据

Skip to main navigation

Skip to Content

Overview

News & Events

Press Releases

Events & Presentations

Financials

Quarterly Results

Annual Reports

SEC Filings

Stock Information

Stock Quote

Analyst Coverage

Governance

Governance Overview

Management

Board of Directors

Committee Composition

Contact the Board

Social Responsibility

Investor Resources

Investor FAQs

Investor Kit

Contact Us

Email Alerts

News Release Details

Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Jul 20, 2026

PDF Version

Highlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts

Includes headline Phase 1 monotherapy data for TLN-121 in relapsed or refractory lymphomas with overall response rate of 84%, complete response rate of 32% and no observed dose-limiting toxicities

Sue Desmond-Hellmann , renowned industry veteran, joined Treeline’s Board of Directors

BOSTON, Mass. , July 20, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools”) today announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (“SEC”) in connection with its previously announced definitive merger agreement with Treeline Biosciences, Inc. (“Treeline”). Upon completion of the all-stock merger, which is expected to occur in the second half of 2026, the combined company is expected to operate under the name Treeline Biosciences Holdings, Inc. and trade on The Nasdaq Stock Market LLC under the ticker symbol “TRLN”.

The registration statement provides an overview of Treeline’s in-house discovery and development organization, deep pipeline, and early clinical and preclinical data that support the development of TLN-121 (BCL6 degrader), TLN-254 (EZH2 inhibitor), TLN-372 (pan-KRAS inhibitor), and TLN-499 (BCL-XL degrader).

Michael Egholm , PhD, President and Chief Executive Officer of Standard BioTools , said, “This is an important transaction milestone as we move closer to completing our merger with Treeline. Treeline’s exciting initial data highlights the immense near and long-term value potential of its pipeline and we are pleased to offer our stockholders the unique opportunity to participate in Treeline’s future growth prospects.”

Josh Bilenker , M.D., co-founder and Chief Executive Officer of Treeline, said, "Strengthening our cash position through this transaction with Standard BioTools will help us accelerate the development of our clinical programs. The encouraging initial clinical data for TLN-121 bode very well for its potential to play a broad role in the management of lymphoma. Moreover, this transaction supports further development of TLN-372, our pan-KRAS inhibitor, and planned clinical entries that include targeted therapy ADCs and previously unliganded targets. I’d also like to formally welcome Sue Desmond-Hellmann to our Board of Directors. We are grateful to be the beneficiaries of the hard-won wisdom and judgment she has accumulated over her remarkable career.”

Headline TLN-121 Clinical Data

TLN-121 is an oral protein degrader of BCL6, a transcriptional repressor protein important to germinal center biology. Most diffuse large B-cell, follicular and T follicular helper peripheral T-cell lymphomas (DLBCL, FL and TFH PTCLs) depend on BCL6 for their growth and survival. Initial data from the dose escalation portion of an ongoing Phase 1 trial demonstrates promising monotherapy activity and tolerability for TLN-121. As of a data cutoff date of March 6, 2026 , across efficacy-evaluable patients with relapsed or refractory DLBCL, FL, or TFH PTCL, the blended overall response rate (ORR) was 84% (n=16/19) and the complete response (CR) rate was 32% (n=6/19), by the Lugano criteria. Complete responses were observed in all 3 histologies. Responses were achieved in heavily pretreated patients who had received 2-8 prior lines of therapy. Of the patients with DLBCL and FL, 50% had received a prior T-/immune-cell engager and 33% of patients had received prior CAR-T therapy. TLN-121 was well tolerated, with no dose-limiting toxicities reported. Most treatment-emergent and treatment-related adverse events were Grade 1. In future expansion cohorts Treeline plans to evaluate TLN-121 both as a monotherapy and in combination with other anti-lymphoma agents.

Interim data readouts for both TLN-121 and TLN-372 are planned for 2027. More precise guidance on the timing of these readouts will be provided in early 2027.

Strong Financial Position

At closing, the combined company is expected to have more than $900 million in pro-forma cash, which is expected to fund operations and support Treeline’s robust development pipeline into 2029. Treeline previously raised approximately $1.2 billion from a syndicate of leading life sciences investors.

Appointment of Sue Desmond-Hellmann to Treeline Board of Directors

Sue Desmond-Hellmann , M.D., M.P.H., served as Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020 and as Chancellor of the University of California, San Francisco from 2009 to 2014. Earlier, in her 14-year career at Genentech , she brought numerous new medicines through development and approval, in roles that included Chief Medical Officer and President of Product Development.

“It is striking how much Treeline has accomplished in just five years,” said Dr. Desmond-Hellman. “I am excited to help the team make the most of the promising science I have seen.”

About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply:  standardbio.com/legal/terms-and-conditions/ .
Patent and License Information:  standardbio.com/legal/notices .

Trademarks:  standardbio.com/legal/trademarks . Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

About Treeline Biosciences, Inc.

Treeline is a clinical-stage biopharma company that aspires to make medicines at the highest level. We match compelling biological targets with proven drug approaches, including small molecule inhibitors, protein degraders, and targeted therapy antibody-drug conjugates, by integrating in-house R&D with leading-edge computational tools. We choose programs with the potential to redefine the treatment of serious diseases. We are led by a team with deep experience across drug discovery and development, working across sites in the U.S. and Europe. Our pipeline spans oncology, neurology and immunology.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the expected timing of the closing of the transaction; the potential benefits of the proposed transaction; the prospective performance and outlook of the combined company’s business, performance and opportunities; the ability of the parties to complete the proposed transaction; the combined company's expected cash at closing and cash runway; Treeline’s product candidates and the potential benefits thereof and potential new indications; Treeline’s expectations with regard to the timing and availability of data from its current and planned clinical trials and preclinical studies; as well as any assumptions underlying any of the foregoing. Th